350MO Omission of Chemotherapy and Addition of the CDK4/6 Inhibitor Ribociclib in HER2-positive and Hormone-Receptor Positive Metastatic Breast Cancer – Second Interim Efficacy Analysis of the Randomized Phase III DETECT V Trial
Annals of Oncology(2024)
AI Read Science
Must-Reading Tree
Example

Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined